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Biosynthesis of butyrate by commensal bacteria plays a crucial role in maintenance
of human gut health while dysbiosis in gut microbiome has been linked to several
enteric disorders. Contrastingly, butyrate shows cytotoxic effects in patients with
oral diseases like periodontal infections and oral cancer. In addition to these host
associations, few syntrophic bacteria couple butyrate degradation with sulfate reduction
and methane production. Thus, it becomes imperative to understand the distribution of
butyrate metabolism pathways and delineate differences in substrate utilization between
pathogens and commensals. The bacteria utilize four pathways for butyrate production
with different initial substrates (Pyruvate, 4-aminobutyrate, Glutarate and Lysine) which
follow a polyphyletic distribution. A comprehensive mining of complete/draft bacterial
genomes indicated conserved juxtaposed genomic arrangement in all these pathways.
This gene context information was utilized for an accurate annotation of butyrate
production pathways in bacterial genomes. Interestingly, our analysis showed that
inspite of a beneficial impact of butyrate in gut, not only commensals, but a few
gut pathogens also possess butyrogenic pathways. The results further illustrated
that all the gut commensal bacteria (Faecalibacterium, Roseburia, Butyrivibrio, and
commensal species of Clostridia etc) ferment pyruvate for butyrate production. On
the contrary, the butyrogenic gut pathogen Fusobacterium utilizes different amino
acid metabolism pathways like those for Glutamate (4-aminobutyrate and Glutarate)
and Lysine for butyrogenesis which leads to a concomitant release of harmful by-
products like ammonia in the process. The findings in this study indicate that
commensals and pathogens in gut have divergently evolved to produce butyrate using
distinct pathways. No such evolutionary selection was observed in oral pathogens
(Porphyromonas and Filifactor) which showed presence of pyruvate as well as amino
acid fermenting pathways which might be because the final product butyrate is itself
known to be cytotoxic in oral diseases. This differential utilization of butyrogenic
pathways in gut pathogens and commensals has an enormous ecological impact
taking into consideration the immense influence of butyrate on different disorders in
humans. The results of this study can potentially guide bioengineering experiments to
design therapeutics/probiotics by manipulation of butyrate biosynthesis gene clusters in
bacteria.
Keywords: butyrate production pathways, gut microbiome, butyrate producers, genome mining, comparative
genomics
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INTRODUCTION
Humans harbor a plethora of micro-organisms comprising of
around 1000 species inhabiting different body sites. Some of them
are beneficial bacteria which help not only in metabolism and
absorption of nutrients by the human host but also in regulation
of our immune system (Bhattacharya et al., 2015). These bacteria
can also influence epithelial cell growth and differentiation
(Schwabe and Jobin, 2013; Sears and Garrett, 2014). The human
body sites with the most diverse microbiome are gut followed
by oral cavity (Corpet et al., 1995). Recent studies have indicated
that microbiome is influenced by various environmental factors.
Any insult to the critical balance of the microbiome composition,
resulting in the outgrowth of harmful bacteria, might be
responsible for triggering diseases/disorders like inflammatory
bowel disease (IBD), diabetes, obesity, periodontitis etc. (Gupta
et al., 2011; Ghosh et al., 2014; Jorth et al., 2014; Tomasello
et al., 2014). Recent studies have also indicated that the onset of
disease cannot be accredited to a single pathogen, but to the entire
microbiome (Schwabe and Jobin, 2013).
The human gut maintains the most diverse microbiome
comprising of bacteria which are beneficial for health and have an
anti-inflammatory effect on intestinal epithelium (Basson et al.,
2000). Majority of these bacteria produce metabolites like short
chain fatty acids (SCFA) that are known to be beneficial for
the host. For example, previous studies have indicated increased
butyric acid in the stool samples of healthy individuals as
compared to those suffering from enteric diseases (Basson et al.,
2000). Similarly, while no significant differences were seen in
propionate level, an elevated acetate level was observed in the
gut of disease cohorts (Weir et al., 2013). These results suggest
that amongst the three bacteria-derived SCFA’s, butyrate might
play a significant role in determining the gut health status
of an individual. This is supported by higher occurrence of
butyrate producing bacteria, like Faecalibacterium, Coprococcus,
and Roseburia in the guts of healthy individuals (Hakansson
and Molin, 2011; Sun and Chang, 2014). On the contrary, the
abundances of these genera were observed to be lower in the
guts of individuals with CRC, IBD, ulcerative colitis, diabetes,
etc. (Dulal and Keku, 2014). Reports have also indicated that
administering butyrate can affect the production of cyclin D3
(Siavoshian et al., 2000; Tang et al., 2011), which may lead to
a cessation of cell in G1 phase of cell cycle and a shift toward
terminal differentiation. Butyrate is experimentally shown to be
a histone deacetylase inhibitor, further emphasizing its role in
reducing cell proliferation by epigenetic regulation (Bordonaro
et al., 2014; Donohoe et al., 2014). Production of butyrate has
been shown to decrease the pH and has been proposed to
prevent the growth of pathogenic organisms like Enterococcus
and Escherichia in the gut (Duncan et al., 2009; Slavin, 2013).
These studies suggest that butyrate produced by gut bacteria has
a positive influence on gut health. Studies have indicated that
butyrate obtained from natural dietary fiber can help maintain
gut homeostasis and reduce the idiopathies of various diseases
that develop due to dysbiosis (Toden et al., 2014).
Another human body site known to be colonized by a wide
diversity of bacteria is the oral cavity. Earlier studies have shown
that contrary to its role in gut, butyrate has a cytotoxic effect
on gingival cells of humans and proves to be pathogenic in
oral environment (Ohkawara et al., 2005). Butyrate has also
been shown to be responsible for release of Reactive Oxygen
species in chronic periodontitis (Chang et al., 2013). Further,
it has been implicated in apoptosis and autophagic cell death
in gingival cells (Ohkawara et al., 2005). The dysbiosis within
oral microbiome is often associated with an increase in butyrate
producing pathogens like Porphyromonas gingivalis, Filifactor
alocis, and Tannerella forsythia and has also been implicated
in diseased conditions like periodontitis (Corpet et al., 1995;
Socransky et al., 1998; Aruni et al., 2015). Thus, while butyrate
is a beneficial metabolite for gut cells, its presence is likely
to show deleterious effects in oral cavity. These differences in
roles of butyrate in different body sites in humans necessitate a
deeper understanding of butyrate production in various bacteria.
In addition, delineating differences in butyrate production
mechanisms of commensals and pathogens is likely to help in
designing better probiotics for improving gut/oral health.
Four major butyrate production pathways exist in bacteria
(Figure 1). These pathways utilize one of the four substrates
namely, pyruvate, glutarate, 4-aminobutyrate and lysine. Each of
these four pathways use butyryl-CoA dehydrogenase electron-
transferring flavoprotein complex (Bcd-Etfαβ) to catalyze
conversion of crotonyl-CoA to butyryl CoA (Chowdhury et al.,
2014). Eventually the final production of butyrate is catalyzed
by either butyryl-CoA:acetate CoA transferase (But) or butyrate
kinase (Buk) (Figure 1). It should also be noted that Glutamate
is used by anaerobic bacteria for production of the substrates
4-aminobutyrate and 2-oxoglutarate while these substrates can be
produced as intermediates of citric acid cycle in aerobic bacteria.
Further, arginine catabolism can also be used in certain bacteria
to biosynthesize 4-aminobutyrate.
One of the in silico studies has utilized just the presence of But
and Buk enzymes (terminal enzymes) as markers for predicting
butyrate production capability by bacteria (Vital et al., 2013).
Similarly, homology-based analysis has been utilized in another
study to identify existence of all genes involved in the butyrate
production in various bacterial genomes (Vital et al., 2014). It is
to be noted that both these methods utilize sequence homology
for prediction of genes. Since some of the genes involved in
the four butyrate pathways are known to be utilized in other
metabolic pathways, the homology-based analyses is expected
to lead to misannotations. In order to overcome this drawback,
apart from identifying homologs of these genes, it is important to
consider their genomic locations in the organisms. The clustered
genomic arrangement of genes comprising each of these butyrate
producing pathways has also been reported earlier in a few
bacteria (Boynton et al., 1996; Li et al., 2012; Whon et al., 2015).
In the present study, a comprehensive Hidden Markov Model
(HMM) based genomic analysis was performed to understand
distribution of butyrate production pathways in commensals
and pathogens inhabiting different environments. Firstly, the
genomic arrangement of these pathways was confirmed and
this context information was utilized for identifying domains
within the cognate butyrate production pathway in 8027 bacterial
genomes. The utilization of juxtaposed genome organization
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FIGURE 1 | Schematic representation of four butyrate production pathways in bacteria. Pyruvate pathway: Pyruvate is converted to crotonyl CoA using
three enzymes, namely, Thiolase (Thl), Hydroxybutyryl dehydrogenase (Hbd) and crotonase/enoyl-CoA hydratase (Cro). 4-aminobutyrate (4Ab) pathway: 4Ab is
converted to crotonyl CoA by the action of AbfH (4-hydroxybutyrate dehydrogenase), 4Hbt (butyryl-CoA:4-hydroxybutyrate-CoA transferase) and AbfD
(4-hydroxybutyryl dehydratase) which also possesses vinyl-acetyl-CoA isomerase activity. Glutarate pathway: 2-oxoglutarate conversion to Crotonyl-CoA involves
2-hydroxyglutarate dehydrogenase (L2Hgdh), glutaconate-CoA transferase (Gct) and 2-hydroxyglutaryl-CoA dehydrogenase (HgCoAd) and Glutaconyl-CoA
decarboxylase (Gcd). Glutamate can be converted to 4-aminobutyrate and 2-oxoglutarate by enzymes Glutamate decarboxylase (Gdc) and Glutamate
dehydrogenase (Gdh) enzymes. Lysine pathway: Lysine is metabolized to Crotonyl-CoA by lysine 2,3-aminomutase (KamA), lysine 5,6-aminomutase (Kam D,E),
3,5-diaminohexanoate dehydrogenase (Kdd), 3-keto-5-aminohexanoate cleavage enzymes (Kce) and 3-aminobutyryl-CoA ammonia lyase (Kal). Acetoacetate
released in the last step can also be converted to Butyate by a few bacteria using butyryl-CoA:acetoacetate-CoA transferase (Ato) enzyme. Crotonyl-CoA, a product
from each of the four pathways, is metabolized to butyryl-CoA by butyryl-CoA dehydrogenase (Bcd). Conversion of butyryl-CoA to butyrate is catalyzed by either two
enzymesphosphate butyryl transferase (Ptb) and Butyrate kinase (Buk), or by butyryl-CoA:acetate CoA transferase (But).
of domains comprising a pathway enabled elimination of
homologous domains which might have different functions
in other metabolic pathways also. This study, to the best
knowledge, is the first to shed light on the distribution of
butyrate production pathways in pathogens versus commensals
across different environmental conditions like gut and oral
cavity in humans. Further, an attempt was made to understand
similarities/differences in butyrate production capabilities as well
as pathways utilized for biosynthesis by gut pathogens and
commensals. In order to further verify our findings, publicly
available 16S rRNA amplicon datasets, corresponding to gut
samples from 443 healthy and 567 diseased individuals, were
analyzed. The results, based on the gene context information
(from bacterial genomes) in combination with the taxonomic
composition, provided valuable insights into the differences
in evolution of butyrate production pathways in commensals
and pathogens in gut. The genome-wide study further gave
insights into the distribution of butyrate production pathways
in bacteria inhabiting the oral cavity in periodontitis patients
as the butyrogenic pathways differed in strains forming the oral
microbiome of these individuals.
RESULTS
Distribution of Butyrate Production
Pathways in Bacteria
In order to evaluate butyrate production capability in various
bacteria, the four known pathways that are utilized by them
for butyrate production (Figure 1) were studied. A preliminary
analysis using HMM based approach (details in Section
“Materials and Methods”) was performed on known butyrate
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producers (e.g., Faecalibacterium, Roseburia, Fusobacteria,
Coprococcus) to confirm the evolutionary conservation of
clustered gene arrangement for all four butyrogenic pathways.
The identified juxtaposed arrangement of genes (Figure 2)
constituting butyrate production pathways is in agreement
with previously reported studies (Boynton et al., 1996; Li et al.,
2012; Whon et al., 2015). Although, the domain order for each
pathway differed across genomes, all genes of a pathway were
found to occur in context with each other. After establishing
the conserved genomic arrangement of butyrate production
pathways, this HMM based analysis was extended to 8027
sequenced genomes (complete and draft) in NCBI to understand
butyrate pathway composition across all bacteria. Results of the
analyses indicated presence of one or more of these pathways
in butyrate producing organisms. 2180 out of 8027 bacteria
were found to have all genes that are involved in butyrate
production from pyruvate. The remaining three pathways
utilizing 4-Aminobutyrate (4Ab), Lysine and Glutarate, were
observed to be present in 41, 110 and 46 genomes, respectively.
Thus, the majority of butyrate producers were found to utilize
pyruvate as substrate.
Role of Electron Transfer Proteins in
Butyryl-CoA Dehydrogenase of
Butyrogenic Bacteria
The Bcd (butyryl-CoA dehydrogenase) enzyme is known to
be a common component utilized by all butyrate producers
(Figure 1). Interestingly, while this gene was found to occur
in context with genes constituting the pyruvate pathway, it was
found to function in trans in other three pathways. The Bcd
protein is known to be composed of three subunits, namely,
α-subunit which acts as butyryl-CoA dehydrogenase (Bcd) and
the β- and γ-subunits which function as electron-transferring
flavoproteins (ETF) (Chowdhury et al., 2014). While all subunits
of this protein were observed to be present in anaerobic butyrate
producers, the β- and γ-subunits were found to be absent in
aerobic butyrate producing bacteria (Supplementary Tables S1
and S2). Interestingly, majority of the bacteria which showed
presence of ETF proteins (β- and γ-subunits) in addition to
dehydrogenase component (α-subunit) were observed to be
mostly gut commensals including Faecalibacterium, Roseburia,
Eubacterium, Odoribacter, Oscillibacter, and Butyrivibrio. The
ETF + dehydrogenase complex was also observed in oral
pathogens like Porphyromonas gingivalis and Filifactor alocis.
These pathogens lead to butyrate production in oral cavity
which, as discussed earlier, is cytotoxic in this environment
and may lead to disorders like periodontitis (Socransky et al.,
1998; Tsuda et al., 2010; Chang et al., 2013; Aruni et al.,
2015). Apart from these bacteria residing in human microbiome,
a few strains of Azotobacter vinelandii, a bacteria known to
thrive in soil environment and those of the thermophillic
Thermoanaerobacteria were observed to possess all three
subunits of Bcd, which is in line with earlier studies (Ueno
et al., 2006). Many sulfate reducing bacteria, identified to possess
pyruvate pathway like Desulfitobacterium, have been reported
to utilize butyrate as an electron donor for sulfate reduction
(Gerritse et al., 1999). Further, studies have hypothesized the role
of ETFs (in Bcd enzymes) in energy conservation in anaerobic
bacteria (Herrmann et al., 2008). Thus, the results from our
FIGURE 2 | Gene organization of the four butyrate production pathways in bacteria. The clustered genomic organization of four butyrate production
pathways has been depicted. The text within the arrows shows the PFAM domain assignments corresponding to each gene in a pathway while the text above the
arrow indicates the gene identifier for which PFAMs were used. Butyryl-CoA dehydrogenase (Bcd), the central enzyme in all four pathways, occurs in genomic
context with the Pyruvate pathway genes and contains the dehydrogenase as well as Electron transferring α and β subunits. The final enzymes phosphate butyryl
transferase (Ptb), butyrate kinase (Buk) and butyryl-CoA:acetate CoA transferase (But) occur on different locations in the bacterial genomes.
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analysis indicate that butyrate biosynthesis might be coupled with
energy conservation in anaerobic butyrate producers.
Since some of the enzymes involved in the above mentioned
four butyrate producing pathways are present in multiple copies
on the genome, the gene context-based information utilized
in the present study (Figure 2) ensured accurate annotation
of all butyrogenic pathways. The predicted butyrate producers
(Supplementary Table S1) from completely sequenced genomes
indicated that not all strains of bacteria were capable of
butyrate biosynthesis. For example, only five out of 18 strains
of Lachnospiracea were found to have one or more of the
butyrate pathways. Results also indicated that different strains of
a bacterial species produce butyrate utilizing different pathways.
For example, while Fusobacterium nucleatum vincentii was found
to possess the 4-aminobutyrate pathway, the other strains of
Fusobacteria contained Glutarate and Lysine pathways. Thus, the
findings of the present study are expected to help in identifying
strains of bacteria that are capable of producing butyrate.
Butyrate Producers in Human Gut
In order to evaluate the role of butyrogenic bacteria in
human gut, publicly available datasets for 16S rRNA amplicons
corresponding to 443 healthy and 567 diseased individuals were
considered. Results of the multivariate data analysis using the
bootstrapped abundance values (details in Section “Materials
and Methods”), indicated higher presence of Firmicutes and
Bacteroidetes in all populations, irrespective of the health status
of the individuals. The butyrate producing Firmicutes were
found to have higher abundances in healthy subjects across all
demographies. For example, genus Faecalibacterium was seen
to have three to fourfold higher abundances in all healthy
subjects, which is in line with earlier reported experimental
studies (Castellarin et al., 2012; Kostic et al., 2012; Warren
et al., 2013; El-Semman et al., 2014). Other genera which
were observed to be high in some of the healthy samples
included Dorea, Blautia, Flavonifractor, Roseburia, Clostridia,
Gemmiger, Coprococcus, Erysipelotrichacea, and Butyricimonas
(Supplementary Figure S1). Eight of the above mentioned
11 genera, prevalent in healthy individuals, are known to
produce butyrate that is useful for gut health. Thus, the higher
abundance of butyrate producers in healthy individuals suggests
the beneficial effect of butyrate on gut health and well being
in humans. It is to be noted that the healthy datasets showed
a higher abundance of Lachnospiracea_incertae_sedis. The term
‘incertae sedis’ refers to strains of family Lachnospiracea which
cannot be assigned to any genus based on the 16S rRNA sequence
homology. Many of these strains have been reported to be
potential butyrate producers which contribute to healthy gut
microbiota (Clarke et al., 2013; Jiang et al., 2015).
The results of the multivariate analyses obtained using
567 diseased patients showed higher abundance of genera
like Streptococcus, Anaerococcus, Veillonella, Escherichia, Rothia,
Campylobacter, Leptotrichia, and Fusobacterium (Supplementary
Figure S1). Interestingly, Fusobacterium is the only butyrogenic
genus which showed twofold higher occurrence in all the patients
suffering from CRC (95 samples) and IBD (101 samples). Also,
although butyrogenic genus Megasphaera was not observed in the
guts of the subjects considered in this study, it has been reported
to have higher abundance in many diseased conditions (Bajaj
et al., 2012; Ling et al., 2013; Chiu et al., 2014). The presence of
butyrogenic bacteria in the guts of diseased individuals calls for
an in-depth comparison of various butyrate production pathways
in likely pathogens and commensals.
Gut Bacteria and Butyrate Production
Pathways
Comparison of Butyrate Production Pathways in
Commensals and Pathogens
The genome mining for four different butyrate production
pathways was performed on all sequenced bacterial genomes
(as described earlier). On mapping the genera showing
differential abundance in healthy versus diseased datasets to the
catalog of butyrate production pathways within each genome
(Supplementary Table S1), different distributions were observed
(Figure 3A).
The results of the analyses indicated the presence of
pyruvate pathway genes involved in butyrate production in
genera which are majorly observed in healthy cohorts, namely
Faecalibacterium, Flavonifractor, Roseburia, Coprococcus, and
Butyricimonas. Another group of bacteria, showing higher
abundance in these cohorts, corresponded to Lachnospiracea
incertae sedis. Thus, we attempted to find butyrate production
pathway distribution within the Lachnospiracea strains which
are known to inhabit gut environs. The analysis indicated
that most sequenced gut Lachnospiracea strains lack butyrate
production pathways, indicating incapability to produce
beneficial butyrate. These strains included Lachnospiracea
8_1_57FAA_uid61885, Lachnospiracea 1_1_57FAA_uid68209,
Lachnospiracea 6_1_63FAA_uid66423, Lachnospiracea
2_1_46FAA_uid66429, Lachnospiracea 9_1_43 BFAA_uid66425,
Lachnospiracea 4_1_37FAA_uid63581, Lachnospiracea
1_4_56FAA_uid68205, Lachnospiracea 2_1_58FAA_uid68203
and Lachnospiracea 5_1_57FAA_uid68199. The only
strains of Lachnospiraceae which inhabit the gut and
carry pyruvate pathway genes for butyrate production
are Lachnospiraceae_bacterium_5_1_63FAA_uid61883 and
Lachnospiraceae_bacterium_3_1_57FAA_CT1. Interestingly,
while only these two strains show phylogenetic similarity to
known butyrogenic gut bacteria (Roseburia intestinalis and
Coprococcus comes), all other strains of Lachnospiraceae found
in gut belong to a different clade. This was also in agreement
with previous study indicating lack of butyrate pathways in
many strains of Lachnospiracea inhabiting the gut (Meehan
and Beiko, 2014). The present study also indicates that all
strains of Roseburia (Roseburia intestinalis and Roseburia
hominis), Faecalibacterium (Faecalibacterium prausnitzii),
Butyrivibrio (Butyrivibrio fibrisolvens), Odoribacter (Odoribacter
splanchnicus), which were observed as commensals in healthy
gut by earlier studies (Ohkawara et al., 2005; Duncan et al.,
2006; Morgan et al., 2012; Heinken et al., 2014), are capable of
producing butyrate using pyruvate pathway. Thus, this study
provides an insight into strains within various genera which
may be responsible for butyrate production in gut. It should
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FIGURE 3 | Butyrate production pathway composition in commensals vs. pathogens. (A) The figure depicts the pathway distribution in bacteria which form
a part of human microbiome. The gut commensals (blue), gut pathogens (orange) and oral pathogens (green) show differential presence of butryogenic pathways.
(B) Clustering of human microbiome bacteria on the basis of pathway presence.
be noted here that this analysis helps to delineate distribution
of butyrate production pathways in strains which belong to
highly abundant genera in human gut. It does not imply that
all these strains would be present in a collected sample, but
indicates which strains within a genus, if present, can possibly
influence the gut health (in terms of butyrate production and
the pathways utilized to biosynthesize the same). It is important
to note that majority of the publicly available metagenomic data
for comparison of taxonomic changes in healthy and diseased
cohorts is based on 16S rRNA which allows classification of
gut microbiota composition mostly at genus level. Thus, the
exact constituent strains of gut microbiota cannot be established
through 16S rRNA metagenomic analysis.
Pyruvate is known to be biosynthesized by the glucose-
metabolizing glycolytic pathway in all bacteria. However, the
results of the present analyses suggest that only butyrogenic
commensals flux some of this pyruvate to bring about butyrate
production. Also, it was observed that gut commensals like
Flavonifractor and few strains of Lachnospiracea possessed not
only pyruvate pathway, but also other butyrate biosynthetic
pathways (Figure 3A). In addition, Figure 3A shows that known
gut commensals like Odoribacter and Oscillibacter (although not
observed in any of the datasets under study) also show the
presence of pyruvate pathway.
Contrary to the commensal bacteria, butyrate biosynthesis
pathways were not identified in majority of pathogenic genera
that were highly abundant in the gut of diseased cohorts. These
genera (described earlier) include all strains of Enterococcus,
Streptococcus, Escherichia, Campylobacter and Leptotrichia. On
the other hand, the three remaining pathways (4Ab, Glutarate
and Lysine) were found in only 0.2% of differentially abundant
genera present in healthy subjects. Interestingly, while the 4Ab
pathway was seen in Fusobacteria and Megasphaera, glutarate
and lysine pathways were identified only in Fusobacteria.
Although a few strains of Fusobacterium nucleatum have been
reported as oral pathogens, a number of invasive strains have
been associated with gastrointestinal diseases also (Allen-Vercoe
et al., 2011). All these gut associated strains of Fusobacterium
(Figure 3A) lack Pyruvate pathway for butyrate production.
In addition studies have indicated Fusobacterium varium to
be present in the gut of diseased individuals (Ohkusa et al.,
2002). Based on the present analyses, lysine and glutarate
pathways were found only in one strain of Fusobacteria, namely
Fusobacterium_nucleatum_ATCC_25586_uid57885 (Figure 3A).
Similarly, Megasphaera elsdenii, another butyrogenic organism,
was found to utilize only 4Ab pathway. The abundance of this
genus has been reported to increase in case of diseased conditions
like obesity, hepatic encephalopathy and bacterial vaginosis (Bajaj
et al., 2012; Ling et al., 2013; Chiu et al., 2014). Thus, the
results of the present study indicate possible correlation between
butyrogenic gut bacteria that belong to genera which show
higher abundance in diseased condition and lack of the pyruvate
pathway. It is also important to note that although pyruvate
utilizing bacterial genera like Faecalibacterium, Roseburia and
Lachnospiracea incertae sedis (explained above) were present
in diseased datasets; their abundances were less than half as
compared to those in healthy datasets. Another observation
from this analysis emphasizes that although 4Ab, Lysine and
Glutarate pathway might be present in commensal bacteria,
they were found to always occur in addition to Pyruvate
pathway. Therefore, specific presence of pyruvate pathway
in commensals emphasizes its importance in differentiating
Frontiers in Microbiology | www.frontiersin.org 6 December 2016 | Volume 7 | Article 1945
fmicb-07-01945 November 30, 2016 Time: 12:40 # 7
Anand et al. Butyrate Production Pathways in Microbiome Bacteria
commensals from pathogens. Figure 3B shows clustering for
human microbiome associated butyrogenic bacteria on the basis
of pathway distribution. The results showed that commensal
bacteria formed a separate cluster distinct from pathogenic
ones. Cluster 1 constituted gut commensals (for which genome
sequences are available) which possessed 100% pyruvate pathway.
Interestingly, the oral pathogens Filifactor and Porphyromonas
also clustered with these gut commensals. On the other hand,
Cluster 2 comprised of Megasphaera and was observed to have
100% of its strains utilizing 4Ab pathway for butyrogenesis.
While Lysine and Glutarate pathways for butyrate production
were observed to occur in 100% of pathogenic Fusobacterium
strains in Clusters 3 and 4, only 11% of Fusobacterium strains
of Clusters 3 and 4 were found to possess 4Ab pathway. Cluster
5 contained 100% of sequenced gut commensal Flavonifractor
and oral pathogen Porphyromonas strains possessing 4Ab, Lysine
and Pyruvate pathways. The presence of oral pathogens in both
Clusters 1 and 5 indicated no specific preference for pathway
utilization in these genera. It should be pointed out here that these
percentages are limited to the sequenced strains of these bacteria
in NCBI.
Pathogenic species of Clostridia were found to be the exception
to the above mentioned observation regarding lack of pyruvate
pathway for butyrate production in pathogenic genera. These
species were found to possess all four genes of this pathway
(Supplementary Table S1). Further analysis showed that these
bacterial species are capable of converting butyrate to butanol,
a pathway absent in all gut commensals. Interestingly, butanol is
known to regulate endospore formation and production of toxins
in pathogenic Clostridia (Karlsson et al., 2000, 2008; Ling et al.,
2014).
Butyrate Production and Ammonia Release in
Diseased Gut
Fusobacteria, one of the genera observed in the guts of
individuals with certain diseases/disorders, were found to contain
butyrate production pathways. However, results of the present
study indicated that instead of pyruvate, Fusobacterium utilizes
4Ab, glutarate and lysine pathways for butyrate production
(Supplementary Figure S2). A detailed genomic analysis of
pathways indicated absence of Bcd enzyme (critical enzyme)
(Figure 1) in majority of Fusobacteria strains. The only exception
was found to be Fusobacterium_nucleatum_ATCC_25586, a
strain known to be a common pathogen in periodontal infections
(Han et al., 2000). Interestingly, this strain was found to have the
Bcd gene flanked by transposase, suggesting possible acquisition
of this gene through horizontal gene transfer event. However,
this gene was not found to be located in the vicinity of the genes
belonging to butyrate pathways. Since Bcd is a common domain
which can be utilized in different pathways, the presence of this
domain in only a single strain of Fusobacterium thus suggests its
involvement in pathways other than butyrate.
Out of the three butyrate production pathways in
Fusobacteria, 4Ab and Glutarate pathways are known to
utilize 4-aminobutyrate (succinate being the precursor) and
2-oxoglutarate as starting substrates respectively. Since anaerobic
bacteria like Fusobacteria lack citrate acid cycle which produces
these substrates as intermediates, they are likely to utilize
Glutamate to form 2-oxoglutarate and 4-aminobutyrate. Thus,
the production of 2-oxoglutarate can only is brought about by
dehydrogenation of Glutamate by Glutamate dehydrogenase in
Fusobacteria, with release of ammonia in the process. Earlier
studies have shown that metabolism of amino acids in the gut
might lead to an increase in pathogenic bacteria like Escherichia,
Enterococcus etc. (Richardson et al., 2013). Also, higher ammonia
in the gut has been shown to increase chances of CRC (Corpet
et al., 1995; Xu et al., 2015). Hence, the ammonia released
as a by-product of butyrate pathways in pathogens probably
impacts gut health. It is to be noted that although, these studies
show the detrimental effect of ammonia released during protein
fermentation, correlation of gut health with ammonia released
during butyrate production by pathogens has not been reported
earlier. The different consequences of butyrate production by
commensals and by pathogens on gut health have also not been
elucidated in literature.
The third butyrate production pathway observed in
Fusobacterium utilizes lysine as a substrate. The enzymes
for lysine biosynthesis are known to be absent in this genus.
Interestingly, results of the genome-context analyses indicated
presence of a lysine permease in the vicinity of the gene
cluster coding for lysine pathway for butyrate production in
Fusobacterium nucleatum ATCC 25586. This suggests that lysine
utilized in this pathway for butyrate production by this strain
is probably obtained from the host. This in turn leads to a
competition with host for lysine, an essential amino acid for the
humans. In addition to extracting an essential resource from
the host, this pathway also leads to release of ammonia which is
deleterious to the gut health.
Apart from the above mentioned three pathways, previous
studies have also reported involvement of methylaspartate
pathway in butyrate production in Fusobacterium varium
(Ramezani et al., 2011), a pathogen observed in human ulcerative
colitis. This pathway (Supplementary Figure S2), involved in
fermentation of Glutamate to Acetyl-CoA and finally Butyryl
CoA, has been observed in various strains of Fusobacteria
(Ramezani et al., 2011). Further analysis in this study on
sequenced genomes (data not shown) showed that amongst the
butyrate producers, this pathway was observed in Fusobacteria
and few pathogenic strains of Clostridium like Clostridium
tetani and Clostridium tetanophorum. The occurrence of this
pathway was completely absent in other butyrogenic gut
commensals. This pathway also produces ammonia while
converting Glutamate to Acetyl CoA. Combining the above
observations, the present study illustrates that the butyrogenic
pathways which utilize amino acids as initial substrates (glutarate,
4Ab, Lysine, methyl aspartate) are prevalent in gut pathogens
and lead to ammonia production that is harmful for gut
health.
The immunomodulation effects of butyrate toward anti
inflammatory response have been studied. It stimulates
regulatory T cells (Treg) to increase the production of IL-10
which is an anti-inflammatory cytokine as depicted in Figure 4A.
Butyrate also stimulates plasma cells to secrete serum IgA which
limits the proliferation of pathogenic bacteria in gut lumen.
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FIGURE 4 | (A) Depiction of beneficial anti-inflammatory immune response
triggered by butyrate biosynthesis in commensal bacteria (shown in green).
The commensal bacteria not capable of producing butyrate have been
depicted in blue. (B) Pro-inflammatory immune response to ammonia
released along with butyrogenesis by gut pathogens.
The pathogenic bacteria which possess butyrogenic pathways
lead to a concomitant ammonia production which increases
inflammation in gut as explained above (Figure 4B). Thus, this
study indicates that pathogens retain butyrogenic pathways
which bring about release of harmful ammonia which might
cause damage to gut integrity leading to higher probability of
pathogen invasion.
Butyrate Producers and Pathways in
Oral Cavity
As discussed earlier, another observation from the genome wide
study of butyrate production pathways was their presence in
pathogens implicated in oral diseases like periodontitis. The
role of butyrate in oral mucosa is contrasting to that in gut
as it is known to be cytotoxic to these cells (Tsuda et al.,
2010). It has also been proven that butyrate in oral cells might
lead to production of Reactive Oxygen Species which might
lead to inflammation (Chang et al., 2013). These butyrogenic
oral pathogens include Fusobacterium nucleatum (discussed
earlier in this manuscript) which primarily utilizes amino
acid metabolism for butyrate production (Jorth et al., 2014).
Additionally, other oral pathogenic bacteria like Porphyromonas
gingivalis, Tannerella forsythia and Filifactor alocis have also
been shown to possess butyrate production pathways (Socransky
et al., 1998; Darveau, 2010; Aruni et al., 2015). Our study
revealed that while all strains of Porphyromonas gingivalis
possessed the Pyruvate, 4-aminobutyrate and Lysine pathways
for butyrate production, Filifactor alocis contained Pyruvate
and Glutarate pathways and Tannerella forsythia possessed
the 4-Aminobutyrate pathway for butyrate production. This
finding is in agreement with an earlier metatranscriptomic study
which showed an upregulation of pyruvate fermentation, lysine
catabolism and glutamate catabolism in chronic periodontis
patients as compared to healthy cohorts (Jorth et al., 2014).
Thus, these results show that contrary to observations for gut
pathogens, oral pathogens do not show any pathway level
preference and possess pyruvate as well as aminoacid fermenting
pathways.
The above observations indicate that an environment like
oral cavity, where Butyrate itself is cytotoxic, does not present a
selection of a particular set of pathways for pathogenic bacteria.
Even the pyruvate fermentation pathway, which does not release
any ammonia, can be utilized by these pathogens to release
butyrate which can itself have a deletrious effect in diseases like
chronic periodontitis.
DISCUSSION
The present study indicates not only increased abundance
of butyrogenic commensal bacteria in healthy cohorts, but
also reveals that majority of them utilize pyruvate as initial
substrate for butyrate production. On the contrary, most of
the pathogenic bacteria do not possess butyrate production
pathways. Interestingly, Fusobacteria which was noticed to
be highly abundant in diseased gut cohorts (CRC and IBD
patients), was the only pathogenic genus observed in gut
to possess butyrate producing capability. Several strains of
Fusobacterium (known to be oral or gut pathogens) utilize
4Ab, Glutarate and Lysine pathways for butyrate production
(Figure 5). It is interesting to note that this pathogen lacks
Citrate or Glyoxylate pathways whose intermediates (succinate
and 2-oxoglutarate, respectively) act as substrates for the first
two pathways (4Ab and Glutarate). Similarly, this pathogen
also lacks lysine biosynthesis genes for producing substrate
for the third pathway (Lysine). Thus, this pathogenic bacteria
probably utilizes either its amino acid metabolic pathways
to produce the substrates or obtain them from the host by
different transporters. The utilization of amino acid metabolizing
pathways ultimately leads to formation of ammonia, a product
known to be harmful for gut cells. On the other hand, obtaining
essential amino acids (like Lysine) from the host is expected to
create a competitive environment in the gut. Thus, the study
emphasizes that it is not only important to know the butyrate
producing capabilities of gut bacteria, but also the biosynthetic
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FIGURE 5 | Distribution of butyrate production pathways in gut bacteria. The figure depicts the distribution of butyrate production pathways in gut bacteria.
The commensal bacteria which produce butyrate have been depicted in green circles and connections have been shown to mark the butyrate production pathways
present in each of them. The commensal bacteria which do not produce butyrate have been depicted in blue circles. The pathogenic bacteria have been depicted in
red circles. The connections to corresponding butyrogenic pathways have been made to depict pathogens that produce butyrate.
pathways used by them as well as the by-products formed in
the process. In addition to gut pathogens, oral pathogens like
Porphyromonas, Filifactor, and Tannerella also show presence
of butyrate production pathways. These bacteria have evolved
to utilize Pyruvate as well as amino acid fermentation for
butyrate production. As explained earlier, the fact that butyrate
itself is pathogenic in oral environment probably does not lead
to an evolutionary selection of specific butyrogenic pathways
for these pathogens. This observation is contrary to what
is observed in case of gut pathogens as they have acquired
harmful ammonia releasing amino acid metabolizing pathways
for butyrate production.
The present study thus illustrates that commensals and
pathogens might have evolved to harbor different pathways for
biosynthesizing the same product. In addition, the different roles
of a metabolite in specific body sites within a host might also
influence distribution and evolution of butyrogenic pathways in
bacteria. The findings from the current analyses can potentially be
applied in future for manipulating butyrate production in order
to improve enteric as well as oral health.
MATERIALS AND METHODS
Genome Mining and Prediction of
Butyrate Biosynthesis Pathways in
Bacteria
Firstly, it was important to confirm that butyrate biosynthesizing
genes occur in context with each other on the genome in a
conserved arrangement. A HMM based analysis (Eddy, 1998) was
performed on the genomes of bacteria known to produce butyrate
through experimental studies. The HMMs corresponding to each
of the domains within genes associated with the four butyrate
production pathways (Figure 2) were obtained from the PFAM
database (Finn et al., 2014). The genomes were scanned for
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butyrate pathways using hmmscan program from HMMER v. 3.1
(Eddy, 1998) with an e-value cutoff of 1e-06. In-house perl scripts
were used to extract domains belonging to each pathway and their
positions on corresponding genomes were obtained using PTT
files. This information was utilized for gene context analysis. In-
house scripts were used to extract the hits to the HMM where
all genes (domains) within a pathway were not only present, but
occurred consecutively (within five genes from each other) on the
genomes. In addition, the order of occurrence of these domains
was noted for each genome.
After confirming the gene arrangement for all the four
pathways in bacteria mentioned above, the analysis was extended
to other bacterial genomes. Protein sequences (FASTA and ptt
files) corresponding to bacterial genomes (complete: 2749; draft:
5503) were downloaded from the NCBI1. The HMM protocol
described above was applied to all genomes and a table cataloging
the genes in each of the butyrate pathways present in these
genomes was obtained (Supplementary Table S1).
Identification of Butyrate Producers in
Human Gut and Oral Cavities
In order to identify butyrogenic bacteria in human gut, publicly
available datasets containing PCR amplicons for 16S rRNA
corresponding to each of the following studies were downloaded
from NCBI-SRA2.
• Gut microbiome of 30 healthy individuals and 30 Colorectal
Cancer patients from Toronto (Canada), Boston (USA),
Houston (USA), Ann Arbor (USA) (Zackular et al.,
2014) (Fastq files available at http://www.mothur.org/
MicrobiomeBiomarkerCRC).
• Gut microbiome of 56 healthy and 46 Colorectal Cancer
subjects from Shanghai (China) (Wang et al., 2012) (SRA
ID: SRP005150).
• Microbiome associated with biopsy samples of 95
Colorectal adenocarcinoma and their adjacent non-affected
tissue from patients in Barcelona (Spain) (Kostic et al.,
2012) (SRA ID: SRP000383).
• Gut microbiome of 302 IBD patients and 168 healthy
individuals from African Caucasian population (Gevers
et al., 2014) (Bioproject ID: PRJNA237362).
• Gut microbiome of 44 type II diabetes patients before and
after (12 weeks) administration of a Chinese decoction (Xu
et al., 2015).
• Gut microbiome of 50 obese and 50 non-obese individuals
from Amish population (NCBI SRA ID SRX021087).
• Oral microbiome of 10 healthy individuals and 10
subgingival periodontitis patients from Chinese population
(Tsai et al., 2016) (NCBI Bioproject ID PRJNA274944).
• Oral micriobiome of 25 healthy and 25 chronic
periodontitis samples from American population (Kirst
et al., 2015) (NCBI Bioproject ID PRJNA269205).
SRA toolkit version 2.3.4 was used to obtain fastq files from the
downloaded data. Quality filtration of the 16S rRNA amplicons
1ftp://ftp.ncbi.nlm.nih.gov/genomes/genbank/bacteria/
2ftp://ftp.ncbi.nlm.nih.gov/sra
was performed to retain only those sequences that had an average
phred score of more than 25. The quality filtered sequences were
scanned to extract only the specific V-regions used in each of
these studies using VXtractor 2.0 (Hartmann et al., 2010).
Taxonomic classification of sequences in each of the samples
was performed using naïve Bayesian classifier implemented in
the Ribosomal Database Project classifier (version 2.8) (Wang
et al., 2007) executed at a bootstrap confidence cut-off of
80%. Based on reliability of alignments obtained at each
taxonomic level, output sequences were classified at phylum,
family and genus levels. The data was then normalized to
obtain relative abundance at various taxonomic levels in each
sample. Only the genera whose median relative abundance
was greater than 0.001% for healthy or diseased datasets were
retained for further analysis. Butyrate producers in the gut
were then identified by mapping species belonging to each
genus to butyrate production pathways listed in Supplementary
Table S1.
Comparison of Butyrate Production
Pathways in Healthy and Dysbiotic
Gut/Oral Cavities
In order to identify differentially abundant taxa in healthy and
diseased cohorts, the obtained normalized taxa abundances in
each of the datasets were subjected to multivariate data analysis.
To remove sample outliers (based on the abundance values),
t-test was performed with 1000 iterations of bootstrapping. In
other words, 80% of the samples were randomly selected in
each iteration from healthy as well as diseased datasets and
a t-test was carried out on these samples. The genera that
appeared as significantly different (in terms of abundance with
a p-value < 0.05) in more than 50% of the iterations (500)
were selected. The differential genera so obtained were analyzed
further to see the differences in distribution of butyrogenic
pathways between commensals and pathogens.
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